Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Operating Income

Last Annual Value

-9.22M

3-Year CAGR

-11%

5-Year CAGR

-121%

10-Year CAGR

-49%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Operating Income

ANEB · NASDAQ
CompanyOperating Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
-9.22M
N/AN/AN/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
-23.08M
N/AN/AN/A
-27.21M
N/AN/AN/A
-146.25M
N/AN/AN/A
-77.63M
N/AN/AN/A
-81.31M
N/AN/AN/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
-9.72M
N/AN/AN/A
-96.82M
N/AN/AN/A
-15.09M
N/AN/AN/A
-57.28M
N/AN/AN/A
-36.51M
N/AN/AN/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72